touchEXPERT OPINIONS

Targeting the underlying pathobiology of esophageal squamous cell carcinoma: The impact of emerging immunotherapies on future clinical practice

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gastrointestinal Oncology, Head and Neck Cancer, Immunotherapy Watch Time: 12 Mins

touchEXPERT OPINIONS Targeting the underlying pathobiology of esophageal squamous cell carcinoma: The impact of emerging immunotherapies on future clinical practice

Leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma (ESCC), and review current and emerging therapies.

Now Playing:
Up Next:
 
Prof. Ken Kato
National Cancer Center Hospital, Tokyo, Japan
Update of current understanding of the pathobiology of esophageal squamous cell carcinoma

Prof. Ken Kato outlines current understanding of the underlying pathobiology of ESCC, including the primary mutations that are implicated, key features of the tumour microenvironment, and potential biomarkers for individualized therapy to improve patient outcomes.

1/3 Next Interview
Leave Feedback
Interview Questions

In this interview, Prof. Ken Kato answers the following questions:

  • What are the most common mutations observed in ESCC?
  • What are the primary features of the tumour microenvironment for ESCC?
  • Which tumour cell‐extrinsic factors can be potentially used as biomarkers to individualize therapy?
  • Which tumour cell‐intrinsic factors can be potentially used as biomarkers to individualize therapy?
About Prof. Ken Kato

Ken Kato, MD, PhD, is a Gastrointestinal Oncologist at the National Cancer Center Hospital in Tokyo, Japan, where he is currently Chief of the Departments of Head and Neck, Esophageal Medical Oncology; Gastrointestinal Medical Oncology; and Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office.

Prof. Kato’s special interests include chemotherapy and chemoradiotherapy for upper-gastrointestinal tumours, multimodal treatment for esophageal cancer, and Biobank and translational research. He has conducted many clinical trials in esophageal cancer, including a phase II trial of chemoradiotherapy for ESCC. He is the group coordinator of the Japan Clinical Oncology Group esophageal cancer study group, and principal investigator for the phase III trial of the comparison of neoadjuvant chemotherapy and adjuvant chemoradiotherapy for locally advanced ESCC, named JCOG1109. The study is ongoing with 600 patients with ESCC. He has also been involved in many clinical trials of immunotherapy for ESCC.

Prof. Ken Kato discloses: Grants or contracts from AstraZeneca, Bayer, Beigene, Bristol Myers Squibb, Chugai, Novartis, MSD, ONO, Shionogi and Taiho; Consulting fees from Beigene, Bristol Myers Squibb and ONO; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bristol Myers Squibb and ONO; and Monitoring Board or Advisory Board fees from Daiichi Sankyo.

 
COMING SOON
Review of current and emerging first-line therapies for esophageal squamous cell carcinoma
Review of current and emerging first-line therapies for esophageal squamous cell carcinoma

Overview of current trials for first-line therapy in ESCC

Key mechanisms of action that are being exploited by agents under investigation

Key efficacy and safety data to date and emerging data of particular relevance for clinical practice

2/3 Next Interview
 
COMING SOON
Review of current and emerging second-line therapies for esophageal squamous cell carcinoma
Review of current and emerging second-line therapies for esophageal squamous cell carcinoma

Overview of current trials for second-line therapy in ESCC

Key mechanisms of action that are being exploited by agents under investigation

Key efficacy and safety data to date and emerging data of particular relevance for clinical practice

3/3 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

In this activity, leading experts in esophageal cancer discuss recent advances in esophageal squamous cell carcinoma (ESCC). They provide an update on current understanding of the underlying pathobiology of ESCC, and consider the impact of current and emerging immunotherapies on clinical practice.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the complex underlying pathobiology of ESCC
  • Analyse the impact of immunotherapy as first-line treatment for patients with ESCC
  • Appraise the impact of emerging treatments on standard of care following failure of later-line therapy for ESCC
Downloads

View and download resources from this activity to support your learning and share with colleagues

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
Feedback Close
Feedback

Please provide feedback for this touchEXPERT OPINIONS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72